Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 129 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp November 24, 2020 Navigating Cancer Survivorship as a Transgender or Non-Binary Person May 5, 2021 Breaking News: The Healthcare Marketplace Re-opens TODAY! February 15, 2021 Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active... August 9, 2022 Load more HOT NEWS Our nurses answer your frequently asked questions about cancer Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... Autumn and Letting Go 3 Steps to Making the Right Decisions for You During Cancer:...
